Novartis gains FDA approval for new MS drug

Sep 22, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.

The approved Swiss drugmaker Novartis' treatment Gilenya to reduce relapses in patients with multiple sclerosis, who experiences loss of balance, and other movement problems.

There is no cure for the disease, but steroids can reduce the duration and severity of symptoms in the short term, and seven treatments on the market have had success in reducing recurrence of symptoms.

All involve daily or regular injections, which doctors say discourages some patients from keeping up with their treatment.

"One of the things Gilenya offers is an alternative to injection or infusion administration," said Dr. Nick LaRocca, of the National Multiple Sclerosis Society. "Many people prefer to take a capsule because they don't like to stick needles into themselves."

Multiple sclerosis causes the body's immune system to attack the protective coatings of the brain and spinal cord. Gilenya works to reduce a type of white blood cell that often attacks the nervous system.

The FDA reviewed the drug under a priority timetable reserved for groundbreaking therapies.

In June, an FDA panel voted 25-0 that Gilenya helps reduce relapses of multiple sclerosis.

Despite the overwhelming endorsement, panelists also had questions about side effects and said patients should receive their first dose under doctor supervision because of the possibility of sudden heart irregularities.

Additionally, panelists said patients should receive routine lung function tests.

Those side effects were less common when patients received the lower of two doses tested by Novartis.

Novartis said Wednesday the FDA approved a 0.5-milligram daily dose of Gilenya.

About 2.5 million people around the world have multiple sclerosis, with an estimated 400,000 of them in the U.S. In the most common form of the disease, patients experience periods of well-being followed by periodic relapses.

Physicians who treat are mindful of safety problems with other recent treatment for the disease. Biogen Idec's drug Tysabri was approved for the condition in November 2004 and pulled from the market the next year after cases of a rare but lethal brain inflammation in some patients. It was reintroduced in 2006 under an FDA-approved distribution program.

Novartis said it is pursuing regulatory approval in Europe and the rest of the world.

The company's stock climbed 33 cents to $56.79 in pre-market trading Wednesday.

Explore further: Johnson & Johnson plans Ebola vaccine testing

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Researchers welcome new multiple sclerosis drug

Jan 23, 2010

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug ...

Multiple sclerosis drug has clinical benefits

Apr 05, 2010

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

New pill to treat multiple sclerosis

Apr 30, 2009

A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London.

Drug improves mobility for some MS patients

Feb 27, 2009

The experimental drug fampridine (4-aminopyridine) improves walking ability in some individuals with multiple sclerosis (MS). That is the conclusion of a multi-center Phase 3 clinical trial, the results of which were published ...

Could estriol be the elixir for MS?

Mar 23, 2007

It has long been common knowledge that pregnant women with multiple sclerosis (MS) experience a sharp drop in the disease's symptoms during the course of their pregnancy.

Recommended for you

Seaweed menace may yield new medicines

21 hours ago

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

User comments : 0